Remove Drug Trials Remove Drugs Remove Vaccine
article thumbnail

JPM23: Vaccine developers as dealmakers, Gilead’s trial tea leaves and building platform companies

Bio Pharma Dive

Moderna’s Stéphane Bancel and Pfizer’s Albert Bourla hinted Monday at greater dealmaking to come for their companies, while Gilead gave investors an update on an important cancer drug trial.

Trials 285
article thumbnail

McMaster drug trial receives more than $6m to test smallpox vaccine against mpox

Pharma Times

Children accounted for the majority of mpox cases and deaths in the DRC since June 2023

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

STAT+: Pfizer scraps half of participants in Lyme disease drug trial due to quality issues

STAT News

Pfizer and partner Valneva are scrapping data from roughly half of the participants in a Phase 3 trial of a Lyme disease vaccine candidate after uncovering quality issues with a third-party clinical trial operator.

Trials 119
article thumbnail

HCP’s use of social media: the good and the not so good

World of DTC Marketing

Doximity was flagged for having anti-vaccine information. The best approach is to use social media to connect HCPs to clincial information and drug trials. A leading pharma company recently sponsored a series of Q&A around the use of their new cancer drug. Most said it had, but they still wanted to know more.

Nurses 294
article thumbnail

Malaria Vaccine a Breakthrough Success with 77 Percent Efficacy

XTalks

After years of disappointing malaria vaccine trials, a malaria shot developed by researchers at the Jenner Institute at the University of Oxford has demonstrated an unprecedentedly high efficacy of 77 percent, and may be the magic bullet the world has been waiting for against the deadly disease.

Vaccine 105
article thumbnail

Mathematical models and computer simulations are the new frontiers in COVID-19 drug trials

Scienmag

The models allow for virtual trials of drugs and vaccines, opening the possibility of pre-assessment for drug and vaccine efficacy against the virus. Researchers are using computer models to simulate COVID-19 infections on a cellular level – the basic structural level of the human body.

Trials 63
article thumbnail

Scepticism in press over Kintor’s COVID-19 US drug trial

pharmaphorum

China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. Reuters quoted Kintor’s chief financial officer Lucy Lu, who said that Kayali was one of its trial investigators.